Merck & Co to buy Schering-Plough in $41 billion deal
This article was originally published in Scrip
Merck & Co is to buy Schering-Plough with a mix of cash and shares valued at $41.1 billion, the companies have announced. The deal comes over a month after another US firm, Pfizer, announced it was to buy Wyeth for $68 billion.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Ipsen is to restart a global Phase III study of palovarotene in an ultra-rare bone disorder after additional analyses of interim data, but a partial clinical hold of the compound's use in patients aged under 14 years of age remains in place.
AveXis/Novartis’s one-time AAV9 vector-based intravenous gene therapy for spinal muscular atrophy, Zolgensma, continues to have beneficial effects up to five years after its administration to babies, and an intrathecal formulation has significant promise in older infants.